Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth ...

Looking back on healthcare technology stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including ...

We recently published a list of 10 Surprising Stocks That Skyrocketed Today. In this article, we are going to take a look at ...

Dave Ramsey Says "Take Social Security at 62" - Here's When That's Actually Brilliant Advice ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.